Roscovitine binds to novel L-channel (Cav1.2) sites that separately affect activation and inactivation

Viktor Yarotskyy, Guofeng Gao, Lei Du, Sindura B. Ganapathi, Blaise Z. Peterson, Keith S. Elmslie

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

L-type (CaV1.2) calcium channel antagonists play an important role in the treatment of cardiovascular disease. (R)-Roscovitine, a trisubstituted purine, has been shown to inhibit L-currents by slowing activation and enhancing inactivation. This study utilized molecular and pharmacological approaches to determine whether these effects result from (R)-roscovitine binding to a single site. Using the S enantiomer, we find that (S)-roscovitine enhances inactivation without affecting activation, which suggests multiple sites. This was further supported in studies using chimeric channels comprised of N- and L-channel domains. Those chimeras containing L-channel domains I and IV showed (R)- roscovitine-induced slowed activation like that of wild type L-channels, whereas chimeric channels containing L-channel domain I responded to (R)-roscovitine with enhanced inactivation. We conclude that (R)-roscovitine binds to distinct sites on L-type channels to slow activation and enhance inactivation. These sites appear to be unique from other calcium channel antagonist sites that reside within domains III and IV and are thus novel sites that could be exploited for future drug development. Trisubstituted purines could become a new class of drugs for the treatment of diseases related to hyperfunction of L-type channels, such as Torsades de Pointes.

Original languageEnglish (US)
Pages (from-to)43-53
Number of pages11
JournalJournal of Biological Chemistry
Volume285
Issue number1
DOIs
StatePublished - Jan 1 2010

Fingerprint

Chemical activation
Calcium Channel Blockers
Torsades de Pointes
L-Type Calcium Channels
Purines
Enantiomers
Pharmaceutical Preparations
roscovitine
Cardiovascular Diseases
Pharmacology

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Yarotskyy, Viktor ; Gao, Guofeng ; Du, Lei ; Ganapathi, Sindura B. ; Peterson, Blaise Z. ; Elmslie, Keith S. / Roscovitine binds to novel L-channel (Cav1.2) sites that separately affect activation and inactivation. In: Journal of Biological Chemistry. 2010 ; Vol. 285, No. 1. pp. 43-53.
@article{8c25762cbfc14d0489a5c46a1e9fd6c4,
title = "Roscovitine binds to novel L-channel (Cav1.2) sites that separately affect activation and inactivation",
abstract = "L-type (CaV1.2) calcium channel antagonists play an important role in the treatment of cardiovascular disease. (R)-Roscovitine, a trisubstituted purine, has been shown to inhibit L-currents by slowing activation and enhancing inactivation. This study utilized molecular and pharmacological approaches to determine whether these effects result from (R)-roscovitine binding to a single site. Using the S enantiomer, we find that (S)-roscovitine enhances inactivation without affecting activation, which suggests multiple sites. This was further supported in studies using chimeric channels comprised of N- and L-channel domains. Those chimeras containing L-channel domains I and IV showed (R)- roscovitine-induced slowed activation like that of wild type L-channels, whereas chimeric channels containing L-channel domain I responded to (R)-roscovitine with enhanced inactivation. We conclude that (R)-roscovitine binds to distinct sites on L-type channels to slow activation and enhance inactivation. These sites appear to be unique from other calcium channel antagonist sites that reside within domains III and IV and are thus novel sites that could be exploited for future drug development. Trisubstituted purines could become a new class of drugs for the treatment of diseases related to hyperfunction of L-type channels, such as Torsades de Pointes.",
author = "Viktor Yarotskyy and Guofeng Gao and Lei Du and Ganapathi, {Sindura B.} and Peterson, {Blaise Z.} and Elmslie, {Keith S.}",
year = "2010",
month = "1",
day = "1",
doi = "10.1074/jbc.M109.076448",
language = "English (US)",
volume = "285",
pages = "43--53",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "1",

}

Roscovitine binds to novel L-channel (Cav1.2) sites that separately affect activation and inactivation. / Yarotskyy, Viktor; Gao, Guofeng; Du, Lei; Ganapathi, Sindura B.; Peterson, Blaise Z.; Elmslie, Keith S.

In: Journal of Biological Chemistry, Vol. 285, No. 1, 01.01.2010, p. 43-53.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Roscovitine binds to novel L-channel (Cav1.2) sites that separately affect activation and inactivation

AU - Yarotskyy, Viktor

AU - Gao, Guofeng

AU - Du, Lei

AU - Ganapathi, Sindura B.

AU - Peterson, Blaise Z.

AU - Elmslie, Keith S.

PY - 2010/1/1

Y1 - 2010/1/1

N2 - L-type (CaV1.2) calcium channel antagonists play an important role in the treatment of cardiovascular disease. (R)-Roscovitine, a trisubstituted purine, has been shown to inhibit L-currents by slowing activation and enhancing inactivation. This study utilized molecular and pharmacological approaches to determine whether these effects result from (R)-roscovitine binding to a single site. Using the S enantiomer, we find that (S)-roscovitine enhances inactivation without affecting activation, which suggests multiple sites. This was further supported in studies using chimeric channels comprised of N- and L-channel domains. Those chimeras containing L-channel domains I and IV showed (R)- roscovitine-induced slowed activation like that of wild type L-channels, whereas chimeric channels containing L-channel domain I responded to (R)-roscovitine with enhanced inactivation. We conclude that (R)-roscovitine binds to distinct sites on L-type channels to slow activation and enhance inactivation. These sites appear to be unique from other calcium channel antagonist sites that reside within domains III and IV and are thus novel sites that could be exploited for future drug development. Trisubstituted purines could become a new class of drugs for the treatment of diseases related to hyperfunction of L-type channels, such as Torsades de Pointes.

AB - L-type (CaV1.2) calcium channel antagonists play an important role in the treatment of cardiovascular disease. (R)-Roscovitine, a trisubstituted purine, has been shown to inhibit L-currents by slowing activation and enhancing inactivation. This study utilized molecular and pharmacological approaches to determine whether these effects result from (R)-roscovitine binding to a single site. Using the S enantiomer, we find that (S)-roscovitine enhances inactivation without affecting activation, which suggests multiple sites. This was further supported in studies using chimeric channels comprised of N- and L-channel domains. Those chimeras containing L-channel domains I and IV showed (R)- roscovitine-induced slowed activation like that of wild type L-channels, whereas chimeric channels containing L-channel domain I responded to (R)-roscovitine with enhanced inactivation. We conclude that (R)-roscovitine binds to distinct sites on L-type channels to slow activation and enhance inactivation. These sites appear to be unique from other calcium channel antagonist sites that reside within domains III and IV and are thus novel sites that could be exploited for future drug development. Trisubstituted purines could become a new class of drugs for the treatment of diseases related to hyperfunction of L-type channels, such as Torsades de Pointes.

UR - http://www.scopus.com/inward/record.url?scp=73649111717&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73649111717&partnerID=8YFLogxK

U2 - 10.1074/jbc.M109.076448

DO - 10.1074/jbc.M109.076448

M3 - Article

C2 - 19887376

AN - SCOPUS:73649111717

VL - 285

SP - 43

EP - 53

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 1

ER -